Endstage Renal Disease Clinical Trial
Official title:
Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease
Individuals receiving dialysis are at risk of heart failure and heart related death. There is an urgent need for treatments that reduce the risk of these problems in patients that require dialysis. Spironolactone is a pill used to prevent heart failure and related deaths in patients that do not require dialysis. It works by blocking a hormone (aldosterone) in your body that causes high blood pressure and can damage the heart. Although spironolactone is very effective in patients that do not require dialysis, we do not know if spironolactone is effective in dialysis patients. Our research will help determine if spironolactone reduces heart failure and heart related deaths in dialysis patients. The purpose of this study is to determine if spironolactone reduces death or hospitalization for heart failure and is well tolerated in patients that require dialysis.
Globally, over 2 million people receive dialysis for end-stage renal disease (ESRD) and 650,000 new patients start dialysis each year. Furthermore, the number of patients receiving dialysis is increasing as access to dialysis in the developing world improves and the prevalence of diabetes and vascular disease rises. Despite technical advances in dialysis, the outcomes for patients with ESRD are poor. Patients have frequent hospitalizations, poor health related quality of life and strikingly, high mortality rates. The most common cause of death in patients receiving dialysis is cardiovascular disease, accounting for >40% of all deaths. Observational studies suggest a causal pathway to cardiovascular death that includes progressive ventricular hypertrophy and dilatation as well as accelerated atherosclerosis. These changes result in myocardial ischemia and cardiac fibrosis that, in turn, lead to heart failure, arrhythmias and cardiac arrest. Strongly implicated in this pathophysiology is aldosterone. Mineralocorticoid receptor antagonists (MRAs) in non-ESRD patients, prevent cardiovascular deaths and small randomized controlled trials of MRAs in ESRD suggests they may reduce death and may be safe. Spironolactone is the most commonly used MRA worldwide. We will conduct a multicentre randomized controlled trial (RCT) to determine if spironolactone reduces cardiac mortality and hospitalizations for heart failure in patients treated with dialysis. This trial is called the Aldosterone bloCkade for Health Improvement EValuation in End-stage renal disease (ACHIEVE). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03023748 -
Intravenous Paricalcitol in Chronic Hemodialysis Patients
|
Phase 4 | |
Terminated |
NCT00776191 -
Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism
|
Phase 4 | |
Completed |
NCT00745914 -
Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients
|
N/A | |
Completed |
NCT02981706 -
Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis
|
N/A | |
Completed |
NCT02946229 -
Data Collection for Next Generation Ultrasound Technology Development
|
N/A | |
Completed |
NCT02966028 -
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
|
Phase 2 | |
Completed |
NCT02976246 -
Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients
|
Phase 4 | |
Recruiting |
NCT02957877 -
LMWH Infusion as Anticoagulation for Home HD
|
Phase 4 | |
Completed |
NCT00745719 -
Parathyroidectomy in Endstage Renal Disease
|
N/A | |
Completed |
NCT03010072 -
The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum
|
Phase 2 | |
Completed |
NCT00745589 -
Sevelamer Hydrochloride in Peritoneal Dialysis Patients
|
N/A | |
Not yet recruiting |
NCT02976688 -
Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis
|
Phase 2/Phase 3 | |
Completed |
NCT02970201 -
Improving Adherence in Renal Dialysis Patients Through Electronic Interventions
|
N/A | |
Withdrawn |
NCT00502268 -
Vitamin D and Carboxy PTH Fragments in Coronary Calcification
|
Phase 4 | |
Completed |
NCT02977117 -
The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis
|
Phase 2 | |
Completed |
NCT02207153 -
Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients
|
||
Completed |
NCT02866214 -
Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT03054454 -
A Podiatry Led MDT Intervention to Reduce the Burden of Foot Disease in Patients With End Stage Kidney Failure
|
N/A |